FY2025 EPS Estimates for Alkermes Cut by Leerink Partnrs

Alkermes plc (NASDAQ:ALKS - Free Report) - Investment analysts at Leerink Partnrs cut their FY2025 EPS estimates for Alkermes in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $1.50 per share for the year, down from their prior estimate of $1.55. The consensus estimate for Alkermes' current full-year earnings is $2.23 per share. Leerink Partnrs also issued estimates for Alkermes' FY2026 earnings at $1.84 EPS.

ALKS has been the subject of several other research reports. Stifel Nicolaus upgraded Alkermes from a "hold" rating to a "buy" rating and upped their price target for the stock from $25.00 to $36.00 in a research note on Tuesday, November 5th. Mizuho upped their price objective on shares of Alkermes from $35.00 to $40.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Cantor Fitzgerald lowered their target price on shares of Alkermes from $48.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, October 25th. Piper Sandler reissued an "overweight" rating and set a $37.00 price target (down from $38.00) on shares of Alkermes in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. lowered their price objective on Alkermes from $32.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Alkermes currently has an average rating of "Moderate Buy" and an average target price of $36.00.

Alkermes Stock Performance

ALKS traded down $0.81 on Thursday, hitting $30.72. 670,465 shares of the company traded hands, compared to its average volume of 1,384,034. Alkermes has a 12-month low of $22.90 and a 12-month high of $32.88. The company has a 50 day moving average of $29.87 and a 200-day moving average of $28.38. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $4.97 billion, a PE ratio of 15.77, a PEG ratio of 1.68 and a beta of 0.49.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Venturi Wealth Management LLC acquired a new position in Alkermes in the 4th quarter valued at about $25,000. V Square Quantitative Management LLC acquired a new position in shares of Alkermes in the third quarter valued at approximately $29,000. Blue Trust Inc. boosted its position in Alkermes by 2,231.5% during the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock worth $49,000 after acquiring an additional 1,629 shares during the last quarter. GAMMA Investing LLC grew its stake in Alkermes by 83.8% in the 3rd quarter. GAMMA Investing LLC now owns 4,204 shares of the company's stock worth $118,000 after acquiring an additional 1,917 shares during the period. Finally, Archer Investment Corp grew its stake in Alkermes by 28.6% in the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company's stock worth $126,000 after acquiring an additional 1,000 shares during the period. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Craig C. Hopkinson sold 100,918 shares of Alkermes stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now owns 44,290 shares of the company's stock, valued at $1,419,494.50. The trade was a 69.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the sale, the director now directly owns 23,013 shares in the company, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,656 shares of company stock worth $7,807,326. 4.89% of the stock is owned by corporate insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.